Part II: Public Payers in the U.S. & Key International Markets

October 3, 2019 4:00 PM - 6:30 PM

MassBio, 300 Technology Square 8th Fl, Cambridge, MA 02139

This event, Part II in a three part series that will explore the value of health, will focus on Medicare and Medicaid in the U.S., existing access and reimbursement issues for innovative therapies and cures, proposed changes to those programs that could impact access and reimbursement, and barriers that exist to innovative payment models. The event will also consider those key international models of assessing value and determining access, how the global landscape is shifting, what the U.S. may be able to learn from them, and highlight emerging markets like China that are moving toward the realm of “must consider” when developing an international strategy. Speakers will share lessons learned and case studies around:

  • How Louisiana Medicaid cured its Hepatitis C population through an innovative payment model with Gilead Sciences 
  • How Biogen and Alnylam approached approvals abroad; lessons learned for navigating health technology assessment (HTA) consolidation in Europe
  • Why a US biotech partnered with a Chinese company to reach the large patient populations in China

We believe this issue is especially timely. We’re at an inflection point, with science that’s been tested for decades finally becoming a reality for patients and a payer system that has not caught up with this level of innovation. Myriad factors are combining to alter the status quo – with policymakers demanding action, and healthcare stakeholders agreeing that we must come up with real solutions. If we don’t come together and address the value equation as an industry and ensure patient access to all new therapies, government or other stakeholders will – and they will likely get it wrong. Download the Part II whitepaper

Drinks and appetizers will be provided. If you're not a MassBio member but are interested in attending, please email communications@massbio.org

Secretary General, European Confederation of Pharmaceutical Entrepreneurs
Alexander Natz is the Secretary General of the European Confederation of Pharmaceutical Entrepreneurs in Brussels and works as a lawyer in the healthcare boutique law firm NOVACOS in Düsseldorf. He advises innovative pharmaceutical and biotech companies, including start-ups, in regulatory and pricing & reimbursement matters from the EU law and German law perspective. From 2008 to 2013, he was Head of the Brussels Office of Bundesverband der Pharmazeutischen Industrie e.V. (BPI). Before, he has been a lawyer at Sträter Law Firm in Germany with a special focus on managed entry agreements and licensing of pharmaceuticals. Alexander has also worked in the field of competition law with the European Commission and in the pharmaceutical industry. As a research assistant at Duke University (USA) he has dealt with international pharmaceutical law. His doctorate was supervised by the former judge at the European Court of Justice, Prof. Dr. Dr. Ulrich Everling. Alexander represents innovative life sciences companies at the EU institutions, before national authorities, HTA agencies, payers and courts. Alexander has a particular expertise in EU regulatory law such as GMP, lifecycle management, distribution and clinical trials, as well as in pricing and reimbursement procedures in Germany. He advises serveral US biotech and medtech companies in market access & government affairs related issues in Germany, offering strategic advice on value demonstration, pricing, tendering and other reimbursement matters. Alexander offers full-service legal support throughout all phases of the AMNOG-procedure, including drafting of dossier, G-BA benefit assessment, price negotiations with the GKV-Spitzenverband and arbitration board proceedings. He has a particular expertise in orphan drugs, medical devices as well as gene & cell therapies. His work also focuses on strategies for early value demonstration towards payers and national HTA bodies next to early patient engagement.